Opko Health Inc. (NYSE:OPK) CEO Phillip Md Et Al Frost purchased 1,800 shares of the company’s stock in a transaction that occurred on Thursday, September 22nd. The shares were acquired at an average cost of $10.63 per share, for a total transaction of $19,134.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $32,622,949.13. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, September 21st, Phillip Md Et Al Frost purchased 1,800 shares of Opko Health stock. The shares were acquired at an average cost of $10.46 per share, for a total transaction of $18,828.00.
  • On Tuesday, September 20th, Phillip Md Et Al Frost purchased 1,800 shares of Opko Health stock. The shares were acquired at an average cost of $10.36 per share, for a total transaction of $18,648.00.
  • On Monday, September 19th, Phillip Md Et Al Frost purchased 1,800 shares of Opko Health stock. The shares were acquired at an average cost of $10.18 per share, for a total transaction of $18,324.00.
  • On Tuesday, September 13th, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The shares were acquired at an average cost of $9.95 per share, for a total transaction of $99,500.00.
  • On Monday, September 12th, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The shares were acquired at an average cost of $9.79 per share, for a total transaction of $97,900.00.
  • On Friday, September 9th, Phillip Md Et Al Frost purchased 3,600 shares of Opko Health stock. The shares were acquired at an average cost of $9.87 per share, for a total transaction of $35,532.00.
  • On Friday, September 2nd, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The shares were acquired at an average cost of $9.28 per share, for a total transaction of $92,800.00.
  • On Thursday, August 25th, Phillip Md Et Al Frost purchased 48,400 shares of Opko Health stock. The shares were acquired at an average cost of $9.06 per share, for a total transaction of $438,504.00.
  • On Wednesday, August 24th, Phillip Md Et Al Frost bought 15,000 shares of Opko Health stock. The stock was purchased at an average cost of $9.24 per share, for a total transaction of $138,600.00.
  • On Tuesday, August 23rd, Phillip Md Et Al Frost bought 29,000 shares of Opko Health stock. The stock was purchased at an average cost of $9.53 per share, for a total transaction of $276,370.00.

Shares of Opko Health Inc. (NYSE:OPK) traded up 2.256% during mid-day trading on Friday, reaching $11.105. The company had a trading volume of 3,889,769 shares. The firm’s 50-day moving average is $9.84 and its 200 day moving average is $10.09. Opko Health Inc. has a 12 month low of $7.12 and a 12 month high of $11.85. The company has a market capitalization of $6.11 billion and a price-to-earnings ratio of 46.464.

Opko Health (NYSE:OPK) last released its quarterly earnings results on Monday, August 8th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.05. The firm earned $357.10 million during the quarter, compared to analyst estimates of $324.11 million. During the same period in the prior year, the business earned ($0.09) EPS. The business’s revenue for the quarter was up 742.2% compared to the same quarter last year. On average, equities research analysts predict that Opko Health Inc. will post ($0.05) earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Opko Health by 0.7% in the second quarter. Vanguard Group Inc. now owns 23,101,477 shares of the company’s stock valued at $215,768,000 after buying an additional 161,981 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in Opko Health by 2.8% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 7,934,967 shares of the company’s stock valued at $74,113,000 after buying an additional 217,965 shares in the last quarter. State Street Corp increased its stake in Opko Health by 11.6% in the second quarter. State Street Corp now owns 7,454,724 shares of the company’s stock valued at $69,627,000 after buying an additional 773,867 shares in the last quarter. BlackRock Fund Advisors increased its stake in Opko Health by 13.2% in the second quarter. BlackRock Fund Advisors now owns 3,212,340 shares of the company’s stock valued at $30,003,000 after buying an additional 375,627 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Opko Health by 6.6% in the first quarter. Geode Capital Management LLC now owns 1,923,455 shares of the company’s stock valued at $19,984,000 after buying an additional 118,512 shares in the last quarter.

OPK has been the topic of several research reports. JPMorgan Chase & Co. set a $14.00 target price on Opko Health and gave the stock a “buy” rating in a research report on Tuesday, August 9th. Standpoint Research initiated coverage on Opko Health in a research report on Friday, June 3rd. They issued a “buy” rating and a $16.00 target price on the stock. Zacks Investment Research lowered Opko Health from a “hold” rating to a “sell” rating in a research report on Friday, July 1st. Deutsche Bank AG dropped their target price on Opko Health from $11.00 to $10.00 and set a “hold” rating on the stock in a research report on Thursday, June 16th. Finally, Oppenheimer Holdings Inc. reaffirmed a “hold” rating on shares of Opko Health in a research report on Thursday, June 16th. Five equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $13.20.

About Opko Health

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NYSE:OPK

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.